June 30, 2021 7:47am

News: Alnylam Pharmaceuticals (ALNY) initiated KARDIA-1, a global P2 study evaluating the efficacy and safety of zilebesiran, an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension. KARDIA-1 will evaluate zilebesiran as monotherapy across different doses administered quarterly and biannually.

Pre-open indications: 2 BUYs: GBT, ALNY; 2 SELLs: VCEL, CRSP; 4 Sells into Strength – Profit: IONS, NTLA, EDIT, CLLS: 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming in July, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are DOWN -0.06% (-22 points), S&P futures are DOWN -0.04% (-2 point) and NASDAQ futures are UP +0.02% (+2 points)

 

U.S. stock futures were lower and all-over-the-map in Wednesday’s pre-open,

European stocks pulled back on pandemic and inflation concerns,

Asia-Pacific stocks were higher on Wednesday despite a slowdown in China’s official manufacturing Purchasing Manager’s Index (PMI),

 

Data Docket: Weekly mortgage applications and pending home sales data are due to be published Wednesday. Payroll firm ADP is scheduled to report on the number of private payrolls added in June.

 

Henry’omics:

So far in the year to date, the S&P 500 is up 14%, while the Nasdaq jumps +12% along with the Dow.

Tuesday’s evening’s recap: “it was programmed to happen. The cell and gene therapy sector “puked-out” many upsides after I stated “cutting some positions for profit before it’s taken from your portfolio” … https://www.regmedinvestors.com/articles/11978

  • The Nasdaq closed UP +27.83 points (+0.19%);
  • The IBB closed up +0.14% and XBI closed down -1.53%;
  • Sector volume was HIGH with 4 of the 6-upside having higher than the 3-month average volume with LOW volume of 7 of 28-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +0.26 points or +1.65% at 16.02;
  • Tuesday’s percentage (%) of the 6-upside were +0.04% (FATE) to +13.63% (NTLA) while the 28-downside ranges from -0.11% (RARE) to -14.81% (VCEL);

Q2/21:

June: 15 positive and 7 negative closes

May:  8 positive, 12 negative closes and 1 holiday

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – Could the share price stay up if it wasn’t “pumped”?

Biostage (BSTG) closed UP +$0.03 to $1.26 with 1,860 shares traded after Monday’s -$0.02 to $1.23 with 1,177 shares traded after Friday’s -$0.10 to $1.25 with 1,00 shares traded, Thursday’s +$0.10 to $1.35 with 1,920 shares traded, Wednesday’s -$0.05 to $1.25 with 11,915 shares traded and last Tuesday’s +$0.09 to $1.30 with 4,779 shares traded. WHAT role is DST Capital “playing” in these on-going “volume-pumping” pricing “moves” – to keep the company from being de-listed?

Question#1: The REAL question to be ANSWERED is WHO is advising them in ALL of these endeavors and was has been the effect and did/has affected conditions within the company and past issues that STILL remain UNRESOLVED?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

SELL into Strength:

Ionis Pharmaceuticals (IONS) closed up +$0.58 to $39.55 after Monday’s +$0.04 to $38.97 and has a positive -$0.03 or -0.08% pre-market indication.

Intellia Therapeutics (NTLA) closed up +$18.18 to $151.61 after Monday’s +$44.60 to $133.43 after Friday’s +$1.99 to $88.83, Thursday’s +$3.25 to $86.84, Wednesday’s +$4.68 to $83.59, Tuesday’s -$0.31 to $78.91 and last Monday’s +$3.30 to $79.22 and has a positive +$3.53 or +2.33% pre-market indication after jumping on news and even with a proposed $400 offering.

Editas Medicine (EDIT) closed up +$2.11 to $46.10 after Monday’s +$2.11 to $43.99, Friday’s +$1.01 to $41.88, Thursday’s +$3.05 to $40.87 and last Wednesday’s +$0.1.41 to $37.82, and has a negative -$0.30 or -0.65% aftermarket indication.

Cellectis SA (CLLS) closed down -$0.41 to $15.85 after Monday’s +$0.64 to $16.26, Friday’s +0.13 to $15.62, Thursday’s $0.69 to $15.49 and last Wednesday’s +$0.19 to $14.80 and has a negative -$0.05 or -0.32% pre-market indication.

 

BUY:
Global Blood Therapeutics (GBT) closed down -$0.73 to $32.45 after Tuesday’s $33.19 and Monday’s $36.44 with a positive +$0.30 or 0.92% pre-market indication.

Alnylam Pharmaceuticals (ALNY) closed down -$0.33 to $165.87 and has news this a.m. about initiation of KARDIA-1, a global 2 study evaluating the efficacy and safety of zilebesiran, an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension.

 

SELL:

Vericel (VCEL) closed down -$10.04 to $57.77 after Monday’s +$0.41 to $67.81 after Friday’s +1.64 to $67.40, Thursday’s $65.76 and last Wednesday’s $64.79, the previous Tuesday’s $61.06 and last Monday’s $61.23 with a negative -$4.61 or -7.89% pre-market indication.

CRISPR Therapeutics (CRSP) closed down -$1.14 to $150.49 after Monday’s +$9.111 to $151.63, Friday’s +$4.76 to $142.52, Thursday's +$7.20 to $137.88 and last Wednesday’s +$1.48 to $130.48 with a negative -$0.49 or -0.33% pre-market indication.

 

 

The BOTTOM LINE: The month, quarter and first half end with again a question of WHAT’S AHEAD during the summer months which can be historically slow.

I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

A true contrarian thought …

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.